CN1939405A - Drop pills for treating coronary heart disease and making method thereof - Google Patents
Drop pills for treating coronary heart disease and making method thereof Download PDFInfo
- Publication number
- CN1939405A CN1939405A CN 200610113541 CN200610113541A CN1939405A CN 1939405 A CN1939405 A CN 1939405A CN 200610113541 CN200610113541 CN 200610113541 CN 200610113541 A CN200610113541 A CN 200610113541A CN 1939405 A CN1939405 A CN 1939405A
- Authority
- CN
- China
- Prior art keywords
- radix salviae
- salviae miltiorrhizae
- extract
- angina pectoris
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 69
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 44
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000284 extract Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000001035 drying Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 235000017276 Salvia Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 239000002826 coolant Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 abstract description 10
- 206010033557 Palpitations Diseases 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 41
- 238000012360 testing method Methods 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 17
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 16
- 206010016256 fatigue Diseases 0.000 description 14
- 229930183118 Tanshinone Natural products 0.000 description 13
- 210000000038 chest Anatomy 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000009413 insulation Methods 0.000 description 11
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 244000132619 red sage Species 0.000 description 10
- 230000035807 sensation Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 8
- 206010040007 Sense of oppression Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 229940039009 isoproterenol Drugs 0.000 description 8
- 208000013220 shortness of breath Diseases 0.000 description 8
- 229940057995 liquid paraffin Drugs 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000006 Nitroglycerin Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000194 supercritical-fluid extraction Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 206010012118 Defect conduction intraventricular Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of dripping pill for treating coronary heart disease, angina pectoris, chest distress and palpitation is prepared from red sage root. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of is raw material with the Radix Salviae Miltiorrhizae, is used for the angina pectoris that coronary heart disease causes, the pharmaceutical preparation and the method for making thereof of uncomfortable in chest and cardio palmus belong to technical field of Chinese medicines.
Background technology
Coronary heart disease is because its sickness rate height, the mortality rate height, and serious harm human healthy, thereby b referred to as " the first human killers ".
Cause of coronary heart disease increases with the growth at age, and degree also increases the weight of with the growth at age.There is data to show, from beginning in 40 years old, every increase by 10 years old, prevalence of coronary heart disease increases 1 times.Male 50 years old, women are after 60 years old, and the coronary atherosclerosis development is rapider, and the danger of same myocardial infarction also increases with advancing age.
World Health Organization (WHO) is classified as follows coronary heart disease: the heart failure in primary cardiac all standing, angina pectoris, myocardial infarction, the ischemic heart desease, arrhythmia.Though coronary heart disease the middle age with sequela, pathological changes coronarius also can originate from the childhood, the ratio of brain worker and physical labourer morbidity is about 2: 1.
For these reasons, study a kind of safe, medicine is effective effectively and rapidly.The medicine that is used for the treatment of this type of disease at present also is of a great variety.Various researchs report points out, the TANSHINONES that contains in the salviamiltiorrhizabung, danshensu, protocatechualdehyde isoreactivity composition can effectively be treated angina pectoris that coronary heart disease causes, disease such as uncomfortable in chest.The type of preparation that its single medical material is processed into through extraction is also very many, as Radix Salviae Miltiorrhizae electuary, danshen cream, Radix Salviae Miltiorrhizae Tabellae, Radix Salviae Miltiorrhizae drop pill, tanshinone capsule, Radix Salviae Miltiorrhizae Injection, Danshen heart-benefiting capsule etc., because the extracting method difference of each preparation finally causes each dosage form curative effect to differ greatly.
The Danshen heart-benefiting capsule records in the 17th of ministry standard, and its preparation process adds starch 88g for getting Radix Salviae Miltiorrhizae extract 200g, Pulvis Talci 10g, and magnesium stearate 2g, mixing incapsulates, and makes 1000, promptly.Wherein the preparation method of Radix Salviae Miltiorrhizae extract is the Radix Salviae Miltiorrhizae behind the decocting of learning from else's experience, and drying is pulverized, add 90% alcohol reflux three times, 2 hours for the first time, second and third time each 1.5 hours, filter respectively, merging filtrate, concentrating under reduced pressure becomes extractum, the ordinary water that adds 10 times of amounts of extractum, the limit edged stirs, and leaves standstill, filter, the precipitate cold drying is pulverized, sieve, promptly.Adopt the extraction exquisiteness method of alcohol extracting-water precipitating fat-soluble active ingredient in the Radix Salviae Miltiorrhizae fully can be separated, make its curative effect be higher than the made preparation of other extracting method, but make behind the capsule and be unfavorable for effective ingredient quick dissolving and absorption in vivo.So provide a kind of reasonable dosage form that can give full play to this curative effect of medication that very important meaning is arranged.
Summary of the invention
Purpose of the present invention just provides a kind of safe, medicine and preparation method thereof effectively and rapidly, can effectively treat the angina pectoris that coronary heart disease causes, uncomfortable in chest and cardio palmus.
Drop pill has become the direction of treatment by Chinese herbs cardiovascular and cerebrovascular diseases medicament preparation development at present, because drop pill has the characteristics of quick performance drug effect, yet Traditional Chinese Medicine Dropping Pill is difficult to make, be prone to conditions of streaking in process of production, the drop pill roundness that makes, slickness and mouldability are undesirable, the Danshen heart-benefiting dropping pill formulation that we invented, the dispersion of medicine in substrate is molecularity and exists, make its enhanced dissolution rate, bioavailability improves, better efficacy, and the drop pill taking convenience, more easy for patients to accept, moreover its preparation technology is simple and direct, the automaticity height is improved production efficiency.
The drop pill that the present invention is made mainly is prepared from by following method:
1) weighting raw materials material Radix Salviae Miltiorrhizae is an amount of;
2) get red rooted salvia that step 1) takes by weighing and decoct with water after, drying is pulverized, it is an amount of to add 90% ethanol, adopts the microwave-assisted extraction method to extract, and filters, merging filtrate, concentrating under reduced pressure becomes extractum, adds the ordinary water of 10 times of amounts of extractum, the limit edged stirs, and leaves standstill, and filters, the precipitate cold drying, pulverize, sieve, promptly get Radix Salviae Miltiorrhizae extract;
3) get step 2) Radix Salviae Miltiorrhizae extract of gained puts in the capacity molten matrix, and mixing splashes in the coolant, makes drop pill, promptly.
Step 2 in the above-mentioned preparation method) the Radix Salviae Miltiorrhizae crude drug adds 4～12 times of water gagings and decocts once under normal pressure, and decocting time 30～90min is preferably and adds 8 times of water gagings and decoct 30min; Step 2) smashing fineness of Radix Salviae Miltiorrhizae extract is preferably 100～200 orders, more preferably 120～150 orders.Substrate described in the step 3) can be any one or two kinds of above mixing the in Macrogol 4000 or 6000, sodium stearate, the glycerin gelatine; Described condensing agent is selected from liquid paraffin, vegetable oil, methyl-silicone oil, kerosene, and being preferably substrate is Macrogol 4000, and condensed fluid is a liquid paraffin.Preferably the weight proportion scope of the substrate behind medicated powder and the heating and melting by 1: 1～1: 10 mixed in the step 3), more preferably mix by 1: 2～2.5 weight proportion scope.The temperature that airtight insulation in the processing step is arranged again is 50～70 ℃, and the temperature on condensed fluid top is remained on 30～35 ℃, and the temperature of condensed fluid is controlled to be 5～10 ℃.
Preparation process condition preferred:
1, the Radix Salviae Miltiorrhizae decocting boils the process conditions selection:
The Radix Salviae Miltiorrhizae crude drug decocts with water, and is for water-solubility impurity composition is wherein removed the impurity when reducing alcohol extraction.To the loss of active ingredient, fry in shallow oil once with 8 times of water gagings when reducing decocting, we are by the investigation to TANSHINONES content in the red rooted salvia behind the decocting, to determine the time of decocting.Concrete grammar is as follows: get totally 9 parts of Radix Salviae Miltiorrhizae crude drug 200g, 30,60,90 minutes each three parts, add 8 times of water gagings respectively and decoct once, with the red rooted salvia drying, measure decocting liquid and concentrate TANSHINONES content in back extractum (relative density 1.35) yield and the Radix Salviae Miltiorrhizae, the results are shown in following table:
Table 1: yield of extract and TANSHINONES relation with contents are investigated behind decocting time and the decocting
| The Radix Salviae Miltiorrhizae decocting time | 10 minutes | 30 minutes | 60 minutes | 90 minutes | ||||||||
| Yield of extract (%) | 20 | 30 | 32 | 33 | ||||||||
| Tanshinone content (%) | 0.37 | 0.35 | 0.36 | 0.35 | 0.33 | 0.34 | 0.27 | 0.26 | 0.26 | 0.25 | 0.23 | 0.23 |
| Average content (%) | 0.36 | 0.34 | 0.26 | 0.24 | ||||||||
| Tanshinone content (%) in the medical material before the decocting | 0.37 | |||||||||||
As can be seen from the above table, along with the lengthening of decocting time, the content of TANSHINONES can reduce gradually in the Radix Salviae Miltiorrhizae, and the concentrated back of water extract yield of extract has tended to balance behind 30min, has begun during to 60min to descend.Boil just in order to remove water-solubility impurity composition in the Radix Salviae Miltiorrhizae because Radix Salviae Miltiorrhizae is carried out decocting, not only most of water-solubility impurity in the medical material can be removed so select to decoct 30min, and can keep the content of tanshinone in the Radix Salviae Miltiorrhizae preferably.
2, the selection of Radix Salviae Miltiorrhizae extraction process behind the decocting
After Radix Salviae Miltiorrhizae pressed the selection process decocting, drying was pulverized, and we adopt supercritical CO respectively with Radix Salviae Miltiorrhizae
2Extract, 90% ethanol be solvent with microwave-assisted extract, alcohol reflux, with the extract aqueous precipitation, with drying precipitate, relatively each extracting method is to the influence of active ingredient, serves as to investigate index with the content of tanshinone.The results are shown in Table 2:
Table 2: Different Extraction Method is to the investigation of the content of tanshinone
Can find out from last table, adopt alcohol reflux tanshinone content to be starkly lower than and use microwave-assisted extraction method and CO
2Super critical extraction.Microwave-assisted extraction method and CO
2Super critical extraction is compared, and uses CO
2Super critical extraction operating technology difficulty is big, requires to have certain pressure, just can make CO
2Liquefaction reaches the purpose of extraction, equipment precision requirement height, the producing cost height, and extraction time be 2～3 times that microwave-assisted extracts; And microwave auxiliary extracting method only needs 20～30min just active ingredient fully to be proposed owing to its extraction time is short, so not only can avoid the problem that tanshinone decomposes gradually because of the prolongation of heat time heating time, content reduces, and the saving energy, simple to operate, and the extraction efficiency height, so preferred extracting method is the microwave-assisted extraction method.
3, the smashing fineness of Radix Salviae Miltiorrhizae extract and the addition of substrate are investigated, are specifically tested as follows:
Get Radix Salviae Miltiorrhizae extract 200g, totally three parts, be crushed to different meshes, add equivalent substrate, investigate its dispersion situation in substrate, the results are shown in Table 3:
Table 3: the extract degree of grinding is investigated with adding substrate magnitude relation
Result of the test shows that grinding particle size is big more, and the sedimentation velocity of medicine in substrate is fast more, and the uniformity of preparation of Chinese medicine content can be subjected to very big influence like this, is unfavorable for stability of formulation; And the addition of substrate is many more, and the medicine uniformity blended with it is good more, but really can reduce the content of dispersion of preparation, increases taking dose, also can increase cost; Pulverizing can make medicine middle part fractionated molecule be destroyed more than granularity is greater than 150 orders, reduces the curative effect of medicine, is 120～150 orders so we select the medicine grinding particle size, and the substrate addition is 2 times of medicated powder.
The temperature of the temperature on the temperature of medicinal liquid insulation, condensed fluid top, condensed fluid is selected when 4, dripping the system drop pill
According to above-mentioned each selection process step, with medicine with after substrate is mixed, insulation, make drop pill, by slickness, rounding property, the formability of investigating prepared drop pill, determine the temperature of the needed medicinal liquid insulation of this drop pill of preparation, the temperature on condensed fluid top, the temperature of condensed fluid, the results are shown in Table 4:
Table 4: the temperature test of the temperature of medicinal liquid insulation, the temperature on condensed fluid top, condensed fluid is investigated
As can be seen from the above table, the temperature of medicinal liquid insulation is that 60 ℃, the temperature on condensed fluid top are that 30～35 ℃, the temperature of condensed fluid the drop pill rounding property, slickness and the formability that make when being 5～10 ℃ are all good.
5, by 3 batches of prepared Danshen heart-benefiting drop pill of this invention selection process, according to drop pill inspection method and relevant content assaying method, carried out stable accelerated test and investigated, investigate and the results are shown in Table 5.
Table 5: the medicine stability accelerated test is investigated
"+" expression is up to specification."-" expression is against regulation.
Can fully find out from last table, the Danshen heart-benefiting drop pill that the present invention is prepared, technology is reasonable, steady quality.
Specific embodiment
After (embodiment 1) Radix Salviae Miltiorrhizae crude drug decocted with water, drying was pulverized, add 90% ethanol microwave auxiliary reflux 25min, extracting solution reclaims ethanol, drying, be crushed to 150 orders, get Radix Salviae Miltiorrhizae extract 200g, put in the fused Macrogol 4000 of 2 times of amounts mixing, insulation (60 ℃), splash in the liquid paraffin of (5～10 ℃), make drop pill, promptly.
After (embodiment 2) Radix Salviae Miltiorrhizae crude drug decocted with water, drying was pulverized, add 90% ethanol microwave auxiliary reflux 25min, extracting solution reclaims ethanol, drying, be crushed to 150 orders, get Radix Salviae Miltiorrhizae extract 200g, put in the fused Macrogol 4000 of 3 times of amounts mixing, insulation (60 ℃), splash in the liquid paraffin of (5～10 ℃), make drop pill, promptly.
After (embodiment 3) Radix Salviae Miltiorrhizae crude drug decocted with water, drying was pulverized, add 90% alcohol reflux three times, 2 hours for the first time, second and third time each 1.5 hours, extracting solution reclaims ethanol, and drying is crushed to 150 orders, get Radix Salviae Miltiorrhizae extract 200g, put in the fused Macrogol 4000 of 2 times of amounts mixing, insulation (60 ℃), splash in the liquid paraffin of (5～10 ℃), make drop pill, promptly.
After (embodiment 4) Radix Salviae Miltiorrhizae crude drug decocted with water, drying was pulverized, and uses CO
2Super critical extraction is extracted 1.5h, reclaim under reduced pressure CO
2, drying is crushed to 150 orders, gets Radix Salviae Miltiorrhizae extract 200g, put in the fused Macrogol 4000 of 2 times of amounts, and mixing, insulation (60 ℃) splashes in the liquid paraffin of (5～10 ℃), makes drop pill, promptly.
After (embodiment 5) Radix Salviae Miltiorrhizae crude drug decocted with water, drying was pulverized, add 90% ethanol microwave auxiliary reflux 25min, extracting solution reclaims ethanol, drying, be crushed to 150 orders, get Radix Salviae Miltiorrhizae extract 200g, put in the fused polyethylene glycol 6000 of 2 times of amounts mixing, insulation (60 ℃), splash in the liquid paraffin of (5～10 ℃), make drop pill, promptly.
Beneficial effect
One, the pharmacodynamics test of medicine of the present invention research
Supply the reagent thing: according to the prepared drop pill of selection process of the present invention.
Positive control medicine: Danshen heart-benefiting capsule, Changyuan Pharmaceutical Industry Co., Ltd., Jilin Prov, lot number 20051101
1, normal pressure hypoxia endurance test mice is 36, and male and female half and half are divided into water matched group, Danshen heart-benefiting capsule matched group, medicine group of the present invention, 12 every group at random.Positive controls and medicine group of the present invention are given the medicine 16.5g/kg of same dose, and the water matched group is given water such as the capacity of grade, equal gastric infusion, every day 3 times, totally 2 days.Measure after day administration 1 hour, outside the matched group that dewaters, each organizes lumbar injection isoproterenol 10mg/kg, after 15 minutes animal is put into the uncovered bottle of the 250ml that the 5g quicklime is housed, and writes down each animal and puts into time to death.The results are shown in Table 6, point out medicine of the present invention can prolong the mice life span.
Table 6: each organizes mice normal pressure anoxia enduring experimental result relatively
| Group | n | Mean time to death |
| The water matched group | 12 | 18.26±2.13 |
| Positive controls | 12 | 15.99±1.33** |
| Medicine group of the present invention | 12 | 11.77±1.52*△ |
Compare with the water matched group, * P＜0.05, △ P＜0.01 is compared with positive control medicine group in * * P＜0.01
The result shows: medicine of the present invention can resist the myocardial ischemia that heavy dose of isoproterenol causes, the mice hypoxia endurance time is prolonged, compare with positive control drug Danshen heart-benefiting capsule and to have significant difference, medicine of the present invention obviously is better than positive controls to prolonging the mice oxytolerant time.
2, isoproterenol causes 24 of ischemic myocardial protection effect rats, and male and female half and half are divided into water matched group, positive controls and medicine group of the present invention at random; give the medicine 16.5g/kg of same dose; the water matched group is given and is waited capacity water, irritates stomach every day 3 times, continuous 10 days.Measure after day administration 1 hour, the fixing II lead electrocardiogram of surveying of animal, voltage 2mv, chart drive speed 50mm/s, the electrocardiographic abnormality person does not include experiment in.After surveying normal ECG, lumbar injection isoproterenol 6mg/kg immediately.Record injection back 30s and 1,2,5,10,20 minute electrocardiogram change.The results are shown in Table 7, table 8.Point out medicine of the present invention that isoproterenol is caused myocardial ischemia the improvement effect is arranged.
Table 7 is respectively organized the rat isoproterenol and is caused myocardial ischemia result relatively (n)
| Group | n | Electrocardiographic abnormality number of animals behind the injection isoproterenol |
| The water matched group | 8 | 8 |
| Medicine group of the present invention | 8 | 4 |
| Positive controls | 8 | 7 |
Table 8 is respectively organized rat different time ECG ST section offset voltage and is changed relatively
| Group | 30s | 1min | 2min | 5min | 10min | 20min |
| The water matched group | 0.06± 0.03(0.50) | 0.09± 0.03(0.70) | 0.07± 0.01(0.55) | 0.08± 0.02(0.75) | 0.06± 0.03(0.43) | 0.03± 0.02(0.23) |
| Positive controls | 0.04±0.01(0.21) * | 0.07± 0.02(0.28) * | 0.07± 0.02(0.33) | 0.04± 0.03(0.28) ** | 0.02± 0.02(0.13) * | 0.07± 0.01(0.05) * |
| Medicine group of the present invention | 0.04± 0.02(0.20) * | 0.04± 0.03(0.10) * | 0.04± 0.02(0.15) | 0.02± 0.03(0.10) ** △ | 0.01± 0.02(0.05) ** △ | 0.01± 0.01(0.03) **△ |
Annotate: () number departs from total millivolt of number for ST section in the corresponding time in the table
Compare with the water matched group,
*P＜0.05,
*△ P＜0.01 is compared in P＜0.01 with positive control drug
The result shows: medicine of the present invention can make the rat ECG ST section depart from remarkable minimizing, shortening recovery time.Show that it has significant protection cardiac muscle and oxygen lack resistant function, and compare with the positive control medicine and to have significant difference, show that medicine of the present invention causes the ischemic myocardial protection effect to isoproterenol and obviously is better than positive control drug.
Two, the clinical observation on the therapeutic effect test of drop pill treatment coronary heart disease of the present invention
(1) physical data
Select angina pectoris patient 397 examples altogether, be the checking group.
1, sex: male's 179 examples among this group patient, women's 200 examples, man: woman=1: 1.12
2, the age: minimum 42 years old of age, maximum 65 years old, 56.61 ± 6.07 years old mean age.Wherein≤and 45 years old 31 example, 46～59 years old 210 example, 〉=60 years old 156 example.
3, state of an illness classification: 140 examples that this group state of an illness is slight, moderate 257 examples.
4, the course of disease: the longest 60 months the course of disease the shortest January, average course of disease 14.79 ± 14.61 months, wherein 1～March 109 example, the 3-6 months 39 example, 〉=June 249 example.
(2) study subject is selected
1, tcm diagnosis standard
(1) suffocating pain over the chest, very then chest pain radiating to the back.
(2) the lighter only feels chest distress, hypopnea.
(3) Electrocardioscopy has the ischemic change or the exercise test positive.
(3) Western medicine diagnose standard (according to International Society of Cardiology and association and World Health Organization's clinical name standardization associating special topic group report " name of ischemic heart desease and diagnostic criteria ")
1, fatigue angina pectoris
The of short duration chest pain outbreak that the situation of increase myocardium requirementing keto quantity is brought out, behind rest or the sublingual administration nitroglycerin, pain often can rapidly disappear.The fatigue angina pectoris can be divided three classes: the preliminary fatigue angina pectoris of a.; The fatigue angina pectoris course of disease is in 1 month.B. stable type fatigue angina pectoris; The fatigue angina pectoris course of disease was stabilized in more than 1 month.C. deterioration type fatigue angina pectoris: the number of times that the equal extent fatigue is brought out, the order of severity and persistent period increase the weight of suddenly.
2, spontaneous angina pectoris
The feature of spontaneous angina pectoris is that the chest pain outbreak does not have obvious relation with the increase of myocardium requirementing keto quantity.Compare with the fatigue angina pectoris, this pain general persistence is longer, and degree is heavier, and is difficult for alleviating for nitroglycerin.This type is not seen enzymic change, and electrocardiogram often occurs that some temporary S-T section is forced down or the T ripple changes.Spontaneous angina pectoris can take place separately or merge existence with the fatigue angina pectoris.
Spontaneous angina pectoris patient's pain seizure frequency, persistent period and pain degree can have different clinical manifestations, and the patient can have and continues the outbreak of bigger chest pain sometimes, similar myocardial infarction, but do not have the characteristic of electrocardiogram and enzyme to change.
The patient of some spontaneous angina pectoris temporary S-T section occurs and raises when outbreak, often be called variant angina pectoris.But when myocardial infarction records this electrocardiogram pattern in early days, can not just use this title.Just send out fatigue angina pectoris, progressive angina pectoris and spontaneous angina pectoris and often be called " unstable angina pectoris ".
(4) case choice criteria
1, includes the case standard in
(1) meets tcm diagnosis standard person;
(2) thoracic obstruction grade scale belongs to slight, moderate, stable type fatigue patient with angina pectoris;
(3) the angina pectoris patient course of disease continued more than 1 month, and in the daily life or the angina pectoris attacks that brings out after the motion weekly more than twice, each outbreak continues more than 3 minutes.
(4) resting electrocardiogram is normal, occurs ischemic ST change or tranquillization during angina pectoris attacks or after the stress test and is ischemic electrocardiographic abnormality person.
More than four must possess simultaneously.
2, get rid of case standard (comprising inadaptation or rejecting standard)
(1) turn out to be coronary heart disease myocardial infarction on inspection, and functions in patients with unstable angina;
(2) thoracic obstruction grade scale belongs to heavier, the stable type of severe, fatigue patient with angina pectoris;
(3) neurosis, climacteric syndrome, cervical spondylosis valve disorder and the cardiac muscle stalk due to pain;
(4) merge the above hypertension of moderate, severe pulmonary insufficiency, severe arrhythmia, serious primary disease such as liver, kidney, hemopoietic system, psychotic;
(5) under-18s, over-65s, gestation or women breast-feeding their children are to this medicine allergy sufferers;
In (6) 6 months myocardial infarction is arranged or the probability person of the myocardial infarction that is about to show effect;
(7) do not meet the standard of including in, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
(5) thoracic obstruction weight split pole standard (according to therapy of combining Chinese and Western medicine angina pectoris in 1979 and arrhythmia forum " angina pectoris and ECG curative effect evaluation criteria ")
1, slight: typical angina pectoris attacks is arranged, each persistent period number minute, pain is shown effect 2～3 times at least weekly, or shows effect every day 1～3 time, but pain is heavy, need suck nitroglycerin sometimes.
2, moderate: for several times typical angina pectoris attacks is arranged every day, and each persistent period number minute was by 10 minutes, and angor is heavier, generally all need suck nitroglycerin.
3, than severe: typical angina pectoris attacks is arranged repeatedly every day, influence activities of daily living (as defecating, wear the clothes etc.).Each outbreak persistent period is longer, need repeatedly suck nitroglycerin.
4, severe pain attack times and degree, all relatively severe is attached most importance to.
(6) clinical symptoms calibration standard (according to the regulation in " new Chinese medicine clinical research guideline ")
1, sensation of oppression over the chest with shortness of breath
Slightly: take place once in a while, only when fatigue, the sense sensation of oppression over the chest with shortness of breath can be alleviated after the rest.
Moderate: happen occasionally, feel sensation of oppression over the chest with shortness of breath during light activity, extended break just can be alleviated, the thing of need taking medicine sometimes.
Severe: often take place, the generation sensation of oppression over the chest with shortness of breath is also arranged during tranquillization, the thing of need taking medicine just can be alleviated.
2, palpitation and uneasiness
Slightly: take place once in a while, after stepping on building or physical exertion, occur;
Moderate: happen occasionally, promptly occur after walking along the street or the slight physical exertion;
Severe: often take place, occur during tranquillization.
(7) verification method
1, Therapeutic Method: 397 routine patients are divided into test group and matched group at random, test group 205 examples wherein, matched group 192 examples.
Test group: take the prepared drop pill of the embodiment of the invention 1
Matched group: take Danshen heart-benefiting capsule (available from the Changyuan Pharmaceutical Industry Co., Ltd., Jilin Prov, lot number 20051101)
Two groups are all write down the time that pain continues and disappear, and trace electrocardiogram once in 30 minutes after medication.
Two groups of cases are observed five angina pectoris attacks medications front and back situation at least.Inaccurate simultaneously other quick-acting antalgesic medicine that uses of medication.
2, observation index
2.1 safety observation
2.1.1 general health check-up project: blood pressure, heart rate, the rhythm of the heart, body weight.
2.1.2 blood, urine, just routine test.
2.1.3 liver, kidney function test.
2.2 health giving quality observation
2.2.1 tcm symptom, the variation of tongue, arteries and veins is observed.
2.2.2 angina pectoris attacks time, number of times, degree, persistent period, alleviate or extinction time, induced factor.
2.2.3 Electrocardioscopy.
2.2.4 dynamic ecg recordings examination or exercise electrocardiogram are done in choosing as required.
(8) record requirement
1, fill in unified form by designing requirement, make itemized record, note observing untoward reaction or unexpected untoward reaction, and tracing study.
2, respectively observe hospital after observing end, write out the observation brief summary after analysis conclusion, the summary, deliver the clinical observation responsible department together with the raw observation table.
3, statistical procedures requires: enumeration data x
2Check; Data are with mean ± standard deviation (x ± s) expression; Measurement data is checked with t; Ranked data are checked with Ridit.
(9) checking result
1, curative effect determinate standard
1.1 chest pain symptom curative effect determinate standard (according to " the clinical research guideline of the treatment by Chinese herbs thoracic obstruction ")
Produce effects: disappeared with interior (containing 3 minutes) pain in 3 minutes after the medication.
Effectively: pain disappearance 3～5 minutes (containing 5 minutes) after the medication.
Invalid: after the medication more than 5 minutes pain just disappear.
Increase the weight of: pain does not disappear or the pain person of increasing the weight of after the medication.
1.2 ECG curative effect evaluation criteria: (according to " the clinical research guideline of the treatment by Chinese herbs thoracic obstruction ")
Produce effects: electrocardiogram returns to normally (or roughly normal) during rest.
Effectively: S-T section reduction person more than the treatment back rise 0.05mv, but does not return to normal; (reaching 25% above person) shoals at the negative T wave that mainly leads; Or the T ripple is upright by smooth change; Chamber or intraventricular block improver.
Invalid: electrocardiogram is preceding identical with treatment substantially.
Increase the weight of: the S-T section reduces more than the 0.05mv before the treatment, deepens (reaching more than 25%) at the T ripple that mainly leads, or upright T ripple flattens smoothly, and smooth T ripple becomes to be inverted, and ectopic cardiac rhythm occurs, atrioventricular block or intraventricular block.
1.3 heart arteries and veins stagnant heat card curative effect determinate standard
By " clinical symptoms calibration standard " with symptom be divided into slightly, moderate, severe, four diseases such as its chest pain, sensation of oppression over the chest with shortness of breath, palpitation and uneasiness, inspection of the tongue are corresponding by 2 minutes, 4 minutes, 6 minutes and dysphoria with smothery sensation is restless, disease is corresponding counted by 1 minute, 2 minutes, 3 minutes for dry mouth and throat etc., add up its total mark, according to " tcm syndrome scoring method ".
Produce effects: treatment back syndrome integrated value descends 〉=2/3.
Effectively: treatment back syndrome integrated value descends between 1/3～2/3.
Invalid: treatment back syndrome integrated value descends≤1/3.
2, efficacy analysis
2.1 angina pectoris (thoracic obstruction) curative effect: 1) test group: observe altogether 205 routine times, wherein produce effects is 76 routine times, and effective 110 examples are inferior, and invalid 19 examples are inferior, total effective rate 90.7%.2) matched group: observe altogether 192 routine times, wherein produce effects is 47 routine times, and effective 102 examples are inferior, and invalid 43 examples are inferior, and total effective rate is 77.6%.As can be seen, the test group curative effect has significant difference apparently higher than matched group.
2.2 angina pectoris persistent period and extinction time: 1) test group: observe angina pectoris average duration 6.55 ± 2.4min, average extinction time 4.04 ± 1.6min after the medication altogether 205 routine times.2) matched group: observe angina pectoris average duration 6.72 ± 1.8min, average extinction time 5.43 ± 6.6min after the medication altogether 192 routine times.The test group curative effect has significant difference apparently higher than matched group.
2.3 observation of curative effect after treating 5 times sees Table 9, table 10.
Table 9: test group observation of curative effect result
| Index | The example number | Produce effects | Effectively | Invalid |
| The sensation of oppression over the chest with shortness of breath palpitation and uneasiness | 40 41 | 12 13 | 21 20 | 7 8 |
Table 10: matched group observation of curative effect result
| Index | The example number | Produce effects | Effectively | Invalid |
| The sensation of oppression over the chest with shortness of breath palpitation and uneasiness | 38 40 | 9 10 | 16 18 | 13 12 |
2.4 treat integration after 5 times: 1) test group: the syndrome integrated value before and after the treatment is respectively 18.88 ± 4.44 and 10.49 ± 5.38, and the treatment back significantly descends P＜0.01.2) matched group: the syndrome integrated value before and after the treatment is respectively 18.47 ± 3.44 and 13.41 ± 1.12, descends P＜0.01 after the treatment to some extent.Through comparing.The test group curative effect has significant difference apparently higher than matched group.
2.5 ECG curative effect: 1) test group: observe 43 example time electrocardiograms altogether and change, produce effects 10 examples are improved 27 examples, invalid 6 examples, total effective rate 86.05%.1) matched group: observe 38 example time electrocardiograms altogether and change, produce effects 6 examples are improved 21 examples, invalid 11 examples, total effective rate 71.05%.The test group curative effect has significant difference apparently higher than matched group.
2.6 (RPP, the i.e. influence of HR * SBP): test group the results are shown in Table 11, and matched group the results are shown in Table 12 to heart rate (HR), systolic pressure (SBP) and myocardial oxygen consumption index.
Table 11: test group is seen the fruit that comes to an end
| HR | SBP | RPP | |
| Control treatment front and back, back difference before controlling | 80.05±11.76 72.12±7.72 7.92±6.67 | 17.27±1.73 13.73±1.62 3.55±0.98 | 1389.1±239.3 1268.3±182.6 ※ 119.23±56.7 |
Annotate: relatively preceding with treatment, ※ P＜0.01.
Table 12: matched group is seen the fruit that comes to an end
| HR | SBP | RPP | |
| Control treatment front and back, back difference before controlling | 81.16±8.76 79.12±8.12 2.04±0.64 | 17.57±2.73 16.94±1.22 0.63±1.51 | 1378.1±218.3 1328.3±162.6 ※ 49.8±55.7 |
Annotate: relatively preceding with treatment, ※ P＜0.05
Through comparative test group and matched group result of the test, the test group curative effect obviously is better than matched group, has significant difference.
Three, the safety analysis of medicine of the present invention
1, medicine of the present invention sees Table 13 to the influence of blood, urine, stool routine and liver, renal function.
Table 13: drug safety observed result of the present invention
| Observation item | The inspection example number | Unusual routine number before controlling | Control the unusual routine number in back |
| Routine blood test Hb WBC | 50 50 | 0 0 | 0 0 |
| Routine urinalysis excrement function liver function SGPT renal function BUN | 51 48 48 48 | 0 0 0 0 | 0 0 0 0 |
The observation of surveying index through above safety examination shows that medicament capsule of the present invention is not seen any toxic and side effects to liver, kidney, blood system aspect, illustrate clinical take safe and reliable.
2. untoward reaction (incidence rate, treatment Countermeasures): do not have.
Four, model case
Slowly * *, male, 59 years old, teacher.
Go to a doctor the date: on August 4th, 98.Patient's angina pectoris medical history 2 years, show effect frequently nearly January, and 3～5 times weekly, continue about 5～6 minutes at every turn, moving then cardiopalmus, chest distress, dysphoria with smothery sensation is restless, and obeying " FUFANG DANSHEN DIWAN " certainly can alleviate, and then needs buccal " nitroglycerine tablets " in the time of bitterly very.Clinical diagnosis is an angina pectoris, belongs to heart arteries and veins stagnant heat card, gives the embodiment of the invention 1 prepared drop pill, sublingual administration when advising its pain, August 2～8 a day priority on the 11st is taken 2 of each buccal five times, chest pain is disappeared, treatment back check electrocardiogram V
4-6The ST section is recovered, and T ripple comparatively upright is smooth, does not occur untoward reaction in the therapeutic process.
Five, observe conclusion
Drop pill of the present invention has blood circulation promoting and blood stasis dispelling, and tranquillizing and allaying excitement is used for the angina pectoris that coronary heart disease causes, uncomfortable in chest and cardio palmus.Inferior by clinical observation 205 examples, total effective rate reaches 86.34%, its clinical efficacy will be higher than positive control medicine-Danshen heart-benefiting capsule on the whole, the angina pectoris patient there is tangible alleviating pain effect, the ischemic electrocardiogram also there is significant improvement effect, sensation of oppression over the chest with shortness of breath, palpitation and uneasiness symptom due to the heart arteries and veins stagnant heat card are also had some improvement, clinical observation 205 examples are not found untoward reaction, detect hepatic and renal function before and after the treatment, blood, urine, just safety indexes such as routine all in normal range.
Claims (9)
1, a kind of Traditional Chinese Medicine Dropping Pill for the treatment of coronary heart disease is prepared from according to following method:
1) weighting raw materials material Radix Salviae Miltiorrhizae is an amount of;
2) get red rooted salvia that step 1) takes by weighing and decoct with water after, drying is pulverized, add 90% alcohol reflux, adopt the microwave-assisted extraction method to extract, filter, filtrate decompression is condensed into extractum, adds a certain amount of ordinary water of extractum, and the limit edged stirs, leave standstill, filter, the precipitate cold drying is pulverized, sieve, promptly get Radix Salviae Miltiorrhizae extract;
3) get step 2) Radix Salviae Miltiorrhizae extract of gained puts in the capacity molten matrix, and mixing splashes in the coolant, makes drop pill, promptly;
2, the Microwave Extraction Equipment that requires described Radix Salviae Miltiorrhizae reflux, extract, to adopt according to right 1;
3, described according to claim 1, the Radix Salviae Miltiorrhizae crude drug decocts with 4～12 times of water gagings;
4, described according to claim 1, it is 30～90 minutes that the Radix Salviae Miltiorrhizae crude drug decocts with water;
5, described according to claim 1, the smashing fineness of Radix Salviae Miltiorrhizae extract is 100～200 orders;
6, described according to claim 1, the smashing fineness of Radix Salviae Miltiorrhizae extract is preferably 150 orders;
7, described according to claim 1, substrate can be any substrate of any one or two kinds of above mixture in Macrogol 4000 (or 6000), sodium stearate, glycerin gelatine, stearic acid, glyceryl monostearate, hydrogenated vegetable oil or the insect wax;
8, described according to claim 1, the weight ratio of medicated powder and substrate is 1: 1～6;
9, according to the described preparation method of claim 1, prepared drop pill blood circulation promoting and blood stasis dispelling, tranquillizing and allaying excitement.In the angina pectoris that causes of treatment coronary heart disease, the purposes of uncomfortable in chest and cardio palmus aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101135410A CN1939405B (en) | 2006-09-30 | 2006-09-30 | Drop pills for treating coronary heart disease and making method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101135410A CN1939405B (en) | 2006-09-30 | 2006-09-30 | Drop pills for treating coronary heart disease and making method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1939405A true CN1939405A (en) | 2007-04-04 |
| CN1939405B CN1939405B (en) | 2012-03-14 |
Family
ID=37958107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101135410A Active CN1939405B (en) | 2006-09-30 | 2006-09-30 | Drop pills for treating coronary heart disease and making method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1939405B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978973A (en) * | 2010-11-05 | 2011-02-23 | 河北大学 | A method for preparing traditional Chinese medicine extract by using microwave |
| CN104524230A (en) * | 2015-02-02 | 2015-04-22 | 王新 | Medicine for conditioning lobar pneumonia in restoration stage and preparation method of medicine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548039B (en) * | 2003-05-20 | 2010-04-28 | 天津天士力制药股份有限公司 | Red sage dripping pill and its preparation |
| CN1823897A (en) * | 2005-12-20 | 2006-08-30 | 王衡新 | Chinese medicinal preparation for antimicrobial and anti inflammation, its preparation method and quality control method |
-
2006
- 2006-09-30 CN CN2006101135410A patent/CN1939405B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978973A (en) * | 2010-11-05 | 2011-02-23 | 河北大学 | A method for preparing traditional Chinese medicine extract by using microwave |
| CN104524230A (en) * | 2015-02-02 | 2015-04-22 | 王新 | Medicine for conditioning lobar pneumonia in restoration stage and preparation method of medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1939405B (en) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101032560A (en) | Chinese medicine composition for treating somnipathy and preparing method thereof | |
| CN1883638A (en) | Compound medicine for treating depression and method for preparing same | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1221280C (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1939405A (en) | Drop pills for treating coronary heart disease and making method thereof | |
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1872273A (en) | Medication composition for treating cardiovascular diseases and cerebrovascular disease, and preparation method | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1872186A (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN1539474A (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1198332A (en) | Tongxinluo medicinal capsule for curing coronary heart disease and angina pectoris and preparation method thereof | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1290547C (en) | Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology | |
| CN1857368A (en) | Medicine composition for treating diabetes | |
| CN101053626A (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris and its preparation method | |
| CN1186054C (en) | Medicine for treating osteoporosis and preparation method thereof | |
| CN1733109A (en) | Soft capsule for treating coronary disease and process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |